Showing results (3091-3100 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|February 7, 2026
Radiotherapy enhances M1 macrophage immunogenic activity through IFNs induction and stimulation in TP53-wild type tumorsChun-Chia Cheng, Hong-Zen Yeh, Zong-Lin Sie, et al.
Cancer Immunology, Immunotherapy : CII|February 12, 2026
Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapySofía Rincón-López, Johelys Atencio-Matos, Olalla Pereda-Sainz, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancerGerald Batist, Petr Kavan, Lance Augustin, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective studyXi Zhong, Tingxuan Huang, Yulu Peng, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trialHyunjae Shin, Youngsu Park, Byeong Geun Song, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2026
Comparative efficacy of combination regimens based on interventional therapy and immune checkpoint inhibitors (ICIs) in patients with intermediate- and advanced-stage hepatocellular carcinoma: a systematic review, meta-analysis, and network meta-analysisJingting Su, Yuejiao Su, Rongyun Mai, et al.
Cancer Immunology, Immunotherapy : CII|January 31, 2026
IL-6 as a driver of bone invasion in IFIT2-depleted oral squamous cell carcinomaKuo-Chu Lai, Chia-Hsun Hsieh, Chen-Hsuan Wang, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2026
CAR-T cells co-expressing IL-7 and CCL19 promote epitope spreading to enhance antitumor immunityKeishi Adachi, Yukimi Sakoda, Tsuneyasu Kaisho, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II studyQianyi Wang, Anwen Xiong, Chenyu Mao, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56bright and CD56dim NK cellsEls P van Hees, Cilia R Pothast, Emma S Pool, et al.
Pageof 652